Outstanding results in the first nine months of 2026

Ipsen delivered strong performance in the third quarter of 2026, with total sales growth of 24.6% at constant exchange rates, driven by continued momentum across Oncology, Rare Disease and Neuroscience. With an upgraded full-year outlook and continued investment in innovation, Ipsen remains focused on delivering sustainable growth and bringing innovative medicines to patients worldwide.

Watch the video to discover the key highlights and what lies ahead.

How useful was this post?

Click on a star to rate it!

Average rating 4.4 / 5. Vote count: 13

No votes so far! Be the first to rate this post.